|
|
|
Of the 30 million dry eye sufferers in the U.S., 86% have
meibomian gland dysfunction (MGD) and may be in need of
an effective treatment.2,3
Dry eye spending is estimated to be $55 billion each year in
the US,4 representing a large opportunity for your practice.
|
|
|
Damon Dierker, OD, FAAO
Eye Surgeons of Indiana
Indianapolis, IN
|
|
Ivan Mac, MD, MBA
Metrolina Eye Associates
Matthews, NC
|
|
|
|
|
|
WEDNESDAY, SEPTEMBER 16
8:00-8:45 PM ET
WEDNESDAY, SEPTEMBER 30
10:00-10:45 PM ET
|
|
|
|
|
Douglas Devries, OD
Eye Care Associates of Nevada
Sparks, NV
|
|
Walt Whitley, OD, MBA, FAAO
Virginia Eye Consultants
Norfolk, VA
|
|
|
|
|
|
TUESDAY, SEPTEMBER 15
8:00-8:45 PM ET
TUESDAY, SEPTEMBER 22
8:00-8:45 PM ET
|
|
|
|
|
Eric Donnenfeld, MD
OCLI Vision
Long Island, New York
|
|
Preeya Gupta, MD
Duke Health
Durham, NC
|
|
|
|
|
|
TUESDAY, SEPTEMBER 29
9:00-9:45 PM ET
TUESDAY, OCTOBER 6
8:00-8:45 PM ET
|
|
|
|
|
Join Alcon and expert faculty to learn how
to serve this growing backlog of patients and expand
your practice with Systane® iLux®.
|
|
|
|
|
ALCON IS THE ONLY PARTNER TO PROVIDE:
|
|
|
|
|
Award-winning
handheld, portable
technology
|
Dry Eye
Excellence practice
support program
(DEEP™)
|
Patient
Retention
Program
|
|
|
|
|
|
|
IMPORTANT PRODUCT INFORMATION
Indication:
The iLUX® Device is indicated for the application of localized heat and pressure therapy in
adult patients with chronic disease of the eyelids, including Meibomian Gland Dysfunction (MGD),
also known as evaporative dry eye.
Potential Adverse Reactions:
Potential adverse effects may include eyelid/eye pain requiring discontinuation of the treatment
procedure, eyelid irritation or inflammation, temporary reddening of the skin, ocular surface irritation or
inflammation (e.g., corneal abrasion, conjunctive edema or conjunctival injection (hyperemia)), and ocular
symptoms (e.g., burning, stinging, tearing, itching, discharge, redness, foreign body sensation, visual
disturbance, sensitivity to light).
Attention:
Please refer to the User Manual for a complete list of contraindications, instructions for use,
warnings and precautions for the iLUX® Device.
References:
1. Alcon data on file, 2019.
2. Tear Film and Ocular Surface Society (TFOS). TFOS DEWS II Report. http://www.tearfilm.org/dettreports-tfos_dew_ii_report/32_30/eng/. Published July 2017.
3. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinicbased patient cohort: a retrospective study. Cornea. 2012;31:472–478.
4. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea.
2011;30:379-387.
|
|
|
|
|
© 2020 Alcon Inc.
|
8/20
|
US-ILU-2000079
|
|
|
Placeholder for 3rd party vendor’s CAN-SPAM language
|
|
|
|
